Value stocks are set up for a successful ten years. The straightforward explanation is that it is extremely improbable that the Federal Reserve would incite
@anglicbakerhouse
another growth stock boom by dropping interest rates to the actual floor in the coming years. Which value stocks are most well-positioned to profit from
@anglicbakerhouse
this positive long-term trend? These three discounted healthcare companies provide an attractive blend of deep value, passive income, and top-line growth.
@anglicbakerhouse
Now, AbbVie (NYSE: ABBV) is through this dynamic process. Humira, the company's best-selling immunology drug, lost its patent protection in Europe in 2018.
@wikimedia
Amgen, a pioneer in the biotech industry (NASDAQ: AMGN), has also lost momentum this year. The biotech's stock has dropped 11.6% so far in 2023
@wikimedia
In 2023, the value of Pfizer (NYSE: PFE) has decreased by more than 20%. Shares of the pharmaceutical company have been declining as a result of the predicted decline in sales
@wikimedia